Form 8-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) October
25, 2005
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
0-30379
|
|
88-0425691
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
of
Incorporation)
|
|
|
|
Identification
Number)
|
|
|
3661
Horseblock Road
|
|
|
|
|
Medford,
NY 11763
|
|
|
|
|
(Address
of principal executive offices)
|
|
|
|
|
631-924-1135
|
|
|
|
|
(Registrant’s
Telephone Number)
|
|
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosures.
(a) |
Included
herein as exhibit 99.1 and hereby incorporated by reference is
an
investment report paid for by the registrant, as indicated in the
report.
|
(b) |
On
October 27, 2005 the Registrant issued the press release titled
“Chembio
Partners with Pfizer in Combating AIDS in Africa” included herein as
Exhibit 99.2 and hereby incorporated by
reference.
|
ITEM
9.01. Financial Statements and Exhibits
(c) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: October 27, 2005
Chembio
Diagnostics, Inc.
By:
/s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer
Exhibit 99.1 investment Report
Exhibit 99.1 Press Release
Exhibit
99.2 - Press Release
CHEMBIO
SUPPORTS PARTNERSHIP FOR CREATING SUSTAINABLE HIV PROGRAMS IN
AFRICA
MEDFORD,
N.Y.--(Market Wire)—Oct. 27, 2005: Chembio Diagnostics, Inc. (CEMI: OTCBB)
announced that it is a Gold Sponsor of the Celebration of Partnership Gala
being
held tonight by the Academic Alliance Foundation (AAF). The gala, which is
being
underwritten by Pfizer Inc. (NYSE:PFE) and chaired by Henry A. McKinnell,
Jr.,
Ph.D., Pfizer’s Chairman and CEO, is honoring Dr. Peter Piot, Under Secretary
General of the United Nations and UNAIDS Executive Director.
Chembio
has pledged to donate ten thousand HIV rapid tests to the Infectious Disease
Institute (IDI) in Uganda, which has been the AAF’s focus project since its
inception in 2003. As recently reported, Uganda has chosen Chembio’s HIV 1/2
Stat-Pak to be the confirmatory test in all of its national rapid testing
protocols. “We are delighted to assist the Infectious Disease Institute and its
partners, including Pfizer and the Academic Alliance Foundation, in efforts
to
combat this disease by creating sustainable programs. Uganda, a leader in
the
fight against HIV/AIDS, as well as the entire region, will benefit from the
work
of the IDI” said Larry Siebert, Chembio’s Chairman and President.
“Chembio’s
generous product donation is greatly appreciated here at the IDI, given our
steady flow of new patient visits. We are even more excited about
Chembio’s accompanying commitment to provide ongoing support and training for
our staff. That contribution signals a willingness to create sustainable
partnerships that work here in Africa - by putting control in the hands of
those
who need it most,” said Keith McAdam, Director of IDI.
The
AAF’s
emphasis is on helping developing countries implement an infrastructure to
combat the daily ravages of AIDS by acquiring the capacity to develop care,
treatment and prevention strategies within their own settings. The AAF believes
in mobilizing and capitalizing on the goodwill of public and private
organizations to aid these affected countries. By galvanizing the public
in
developed countries, the countries most affected will be able to sustain
themselves using these international resources. The Infectious Disease Institute
(IDI) of Uganda, built in 2003 at Makerere University, is funded by the AAF
through major support of Pfizer. The IDI facilitates attainment of AAF’s
objectives and is striving to become the center of excellence for treating
HIV/AIDS in Africa.
Chembio’s
rapid HIV tests include the HIV 1/2 Stat-Pak™, HIV 1/2 Stat-Pak Dipstick™ and
the HIV 1/2 Sure Check ™. These tests are simple, safe, cost-effective and
operator-friendly requiring less than five microliters of blood from a
fingerstick.
ABOUT
THE ACADEMIC ALIANCE FOUNDATION
Information
about the Infectious Disease Institute and the Academic Alliance Foundation
can
be viewed at www.academicalliancefoundation.org.
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc. (Chembio) possesses expertise in the development and
manufacturing of rapid test products for various infectious diseases, including
HIV, Tuberculosis and Chagas Disease. References to Chembio Diagnostics,
Inc.
may actually refer to Chembio Diagnostic Systems, Inc., the 100%-owned
subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock
Road, Medford, NY 11763.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve
risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited
to
Chembio's ability to obtain additional financing and the demand for Chembio's
products. Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur
after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated events.
Factors that may impact Chembio's success are more fully disclosed in Chembio's
most recent public filings with the U.S. Securities and Exchange
Commission.